Nausea incidence with GLP-1 therapies varies by agent, dose, and population, but current research indicates that roughly one in five to one in two users experience some nausea, most often during the first weeks of therapy
She subsequently enrolled in a clinical trial for targeted therapy.On February 2, 2025, CT scans identified multiple liver metastases, and everolimus was initiated ( Figure 4 )
coli may protect their cells against ferroptosis by assaying Fe 2+ to deplete the substrates for the Fenton reaction and catalytically decomposing hydrogen peroxide (HO), ultimately suppressing the production of hydroxyl radical (OH) (Long et al., 2024)
Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures
Integration of full-length transcriptomes and anthocyanin metabolite analysis for understanding fruit coloration mechanism in Schisandra chinensis
Great option for cutting